Examination of the adverse event occurrence suppression effect by K15 lactic acid bacteria intake during preoperative chemotherapy for esophageal cancer - K15 lactic acid bacteria for esophageal cancer

Miyata Hiroshi0 个研究点目标入组 50 人开始时间: 2021年4月5日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•(1) Endoscopic biopsy confirmed histologically to be esophageal cancer (regardless of tissue type).
•(2) Patients with resectable esophageal cancer that does not show metastases to other organs by pre-treatment imaging and who are scheduled to undergo radical surgery for esophageal cancer after preoperative chemotherapy.
•(3) Dysphagia score 0-2
•(4) Age: 20 to 80 years old
•(5) ECOG Performance status: 0-1
•(6) Patients whose functions of major organs (bone marrow, heart, lungs, kidneys, etc.) are well preserved.
•(7) Cases where written consent was obtained from the patient
•(8) It can be judged that esophagectomy can be performed by thoracotomy (or thoracoscopic) laparotomy (or laparoscopic).

•(1) Active double cancer (excluding double cancer that can be cured by local treatment)
•(2) Cases with a history of irradiation for head and neck cancer
•(3) Cases with severe absorption disorders
•(4) Patients with severe passage obstruction who require central parenteral nutrition or nutritional support with nasogastric tube during registration
•(5) Cases in which the dose of the initial preoperative chemotherapy needs to be reduced due to decreased organ function or failure
•(6) Cases of inflammatory bowel disease
•(7) Patients with poor glycemic control during treatment (HbA1c>8.0%)
•(8) Cases with milk protein allergy
•(9) Cases with a history of gastrointestinal resection
•(10) Cases that the investigator considers inappropriate
•(11) Patients with severe mental disorders who cannot understand the contents of the test
•(12) Patients currently undergoing or having a history of diagnosis of xerostomia

发起方

Miyata Hiroshi